Cisplatin as second-line chemotherapy for docetaxel-refractory prostate cancer
Posted Mar 28 2011 12:00am
An Italian research team has published data from a small Phase II clinical trial suggesting that cisplatin + prednisone has activity in the treatment of men with castration-resistant prostate cancer (CRPC) who have already progressed after treatment with a docetaxel-based chemotherapy regimen.
Between April 2007 and January 2010, Buonerba et al. enrolled a series of 25 men with progressive CRPC, all previously treated with docetaxel. The patients were all treated with cisplatin (75 mg/m2) every 3 weeks) and prednisone (10 mg/day).
Their trial results are as follows:
The average (median) age of the patients was 65 years.
All patients were evaluable for PSA response and toxicity; 13/25 patients (52 percent) were evaluable for measurable disease.
A total of 170 cycles of cisplatin chemotherapy were administered.
The average (median) dose intensity of cisplatin corresponded to 96 percent of the maximum dose intensity.
5/25 patients (20 percent) had a PSA reduction of > 50 percent.
3/13 patients with measurable disease had a partial response to treatment.
The average (median) progression-free survival was 24 weeks (range, 15-24 weeks).
The average (median) overall survival was 55 weeks (range, 46-64 weeks).
Although cisplatin + prednisone seems to have been an active regimen in men with docetaxel-refractory CRPC in this study (with at least an “acceptable” toxicity profile), it is not clear from the abstract of this study what percentages of these 25 men had evident metastasis at the time of treatment. We know that 13/25 men had “measurable” metastatic disease, but was there evidence of metastasis in the other 12 patients too, or did these patients simply have undocumentable “micrometastsic” disease?
An Italian research team has published data from a small Phase II clinical trial suggesting that cisplatin + prednisone has activity in the treatment of men with castration-resistant prostate cancer (CRPC) who have already progressed after treatment with a docetaxel-based chemotherapy regimen.
Between April 2007 and January 2010, Buonerba et al. enrolled a series of 25 men with progressive CRPC, all previously treated with docetaxel. The patients were all treated with cisplatin (75 mg/m2) every 3 weeks) and prednisone (10 mg/day).
Their trial results are as follows:
Although cisplatin + prednisone seems to have been an active regimen in men with docetaxel-refractory CRPC in this study (with at least an “acceptable” toxicity profile), it is not clear from the abstract of this study what percentages of these 25 men had evident metastasis at the time of treatment. We know that 13/25 men had “measurable” metastatic disease, but was there evidence of metastasis in the other 12 patients too, or did these patients simply have undocumentable “micrometastsic” disease?